Literature DB >> 21648024

Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater.

David R Rubinow1, Susan S Girdler.   

Abstract

It is increasingly axiomatic that depression has widespread adverse physiological effects and, conversely, that a variety of physiological systems impact the risk for developing depression. This convergence of depression and altered physiology is particularly dramatic during midlife--a time during which reproductive failure presages dramatic increases in prevalence of both heart disease and depression. The potentially meaningful and illuminating links between estrogen deficiency, cardiovascular disease (CVD), and depression have largely been obscured, first by assertions, subsequently repudiated, that the perimenopause was not a time of increased risk of depression, and more recently by the denegration of hormone replacement therapy by initial reports of the Women's Health Initiative. Increasingly, however, research has led to unavoidable conclusions that CVD and depression share common, mediating pathogenic processes and that these same processes are dramatically altered by the presence or absence of estrogen (E2). This review summarizes data supporting these contentions with the intent of placing depression and estrogen therapy in their proper physiologic context.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21648024     DOI: 10.1002/da.20833

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  6 in total

Review 1.  Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.

Authors:  Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuron       Date:  2019-04-03       Impact factor: 17.173

2.  Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.

Authors:  Jennifer L Gordon; David R Rubinow; Tory A Eisenlohr-Moul; Kai Xia; Peter J Schmidt; Susan S Girdler
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

Review 3.  Estrogen and extinction of fear memories: implications for posttraumatic stress disorder treatment.

Authors:  Ebony M Glover; Tanja Jovanovic; Seth Davin Norrholm
Journal:  Biol Psychiatry       Date:  2015-02-16       Impact factor: 13.382

4.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.

Authors:  Ronald S Duman; George K Aghajanian; Gerard Sanacora; John H Krystal
Journal:  Nat Med       Date:  2016-03       Impact factor: 53.440

5.  Pilot Data on the Feasibility And Clinical Outcomes of a Nomegestrol Acetate Oral Contraceptive Pill in Women With Premenstrual Dysphoric Disorder.

Authors:  Emily Robertson; Caroline Thew; Natalie Thomas; Leila Karimi; Jayashri Kulkarni
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-24       Impact factor: 5.555

6.  Do premenopausal women with major depression have low bone mineral density? A 36-month prospective study.

Authors:  Giovanni Cizza; Sima Mistry; Vi T Nguyen; Farideh Eskandari; Pedro Martinez; Sara Torvik; James C Reynolds; Philip W Gold; Ninet Sinaii; Ninet Sinai; Gyorgy Csako
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.